Altogether, these studies support human DASS proteins as potentially novel therapeutic targets for tackling diet-induced obesity, type 2 diabetes, kidney stone, and fatty liver, in addition to other metabolic and neurological disorders [1,2,3]. Here, LTBP3 is linked to obesity due to melanocortin 4 receptor deficiency.